Atossa Genetics (ATOS) Expected to Announce Earnings on Tuesday

Atossa Genetics (NASDAQ:ATOS) is expected to be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Atossa Genetics to post earnings of ($0.99) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

Atossa Genetics Stock Down 6.6%

ATOS traded down $0.38 during trading on Tuesday, hitting $5.48. The company’s stock had a trading volume of 164,520 shares, compared to its average volume of 118,398. Atossa Genetics has a twelve month low of $3.76 and a twelve month high of $19.35. The stock’s fifty day moving average price is $5.09 and its 200-day moving average price is $8.48. The firm has a market capitalization of $47.15 million, a P/E ratio of -1.52 and a beta of 1.25.

Institutional Investors Weigh In On Atossa Genetics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in Atossa Genetics in the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC increased its stake in Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after buying an additional 514,175 shares during the last quarter. Geode Capital Management LLC increased its stake in Atossa Genetics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after buying an additional 9,627 shares during the last quarter. Finally, State Street Corp increased its stake in Atossa Genetics by 31.2% in the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after buying an additional 141,990 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ATOS has been the topic of several research reports. HC Wainwright upped their price objective on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Ascendiant Capital Markets dropped their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Atossa Genetics currently has an average rating of “Hold” and a consensus target price of $36.33.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.